Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Outcomes and toxicity profiles of two-drug versus three-drug neoadjuvant chemotherapy for locally advanced cervical cancer in a setting without radiotherapy: Insights from Malawi.

Irene Alinafe Chidothe-Chisale, George Kassim Chilinda, Friday Odala et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17503

e17503 Background: Malawi has the second-highest global incidence and mortality rate for cervical cancer. For locally advanced cervical carcinoma (LACC),...

Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for <i>BRAF</i> V600E-mutated anaplastic thyroid cancer ( <i>BRAF</i> m-ATC): A multicenter phase 2 trial.

Mark Zafereo, Rui Jennifer Wang, Naifa Lamki Busaidy et al. Jun 01, 2025 pp. 6008-6008 10.1200/jco.2025.43.16_suppl.6008

6008 Background: ATC patients present with advanced, often surgically unresectable disease with historically dismal prognosis. Median PFS and OS of DT wit...

Feasibility of door-to-door HPV DNA screening using self-collected vaginal swabs for early detection of cervical cancer in rural India.

Shailendra Dandge, Kalpana Betha, Sameer Valsangkar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17526

e17526 Background: Cervical cancer is the second most common cancer among women in India, with rural women disproportionately affected due to limited awar...

Association of co-administration of a vaccine with immune checkpoint inhibitors with survival.

Justin Dejia Wang, Leah Puglisi, Samantha R. Bagsic et al. Jun 01, 2025 pp. 11151-11151 10.1200/jco.2025.43.16_suppl.11151

11151 Background: Patients undergoing chemotherapy are less likely to complete recommended routine vaccination. Vaccination during immune checkpoint inhib...

Evaluating the efficacy of tyrosine kinase inhibitors and other targeted therapies in imatinib-resistant gastrointestinal stromal tumors: A comprehensive Bayesian network meta-analysis.

Umme Kulsum, Ibrahim Khalil, M. Rafiqul Islam et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16475

e16475 Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, primarily driven by KIT o...

Novel anatomical concept and standardized technique for single-port laparoscopic para-aortic lymphadenectomy.

Hua Tu, Zhimin Liu, Zejian Lin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17621

e17621 Background: Para-aortic lymphadenectomy (PAL) plays an important role in the treatment of gynecological cancers. Laparoscopic PAL is a technically...

Survival association of PIK3CA in HPV-driven head and neck squamous cell carcinoma (HNSCC).

Kelly Bridgham, Tolulope Tosin Adeyelu, Andrew Elliott et al. Jun 01, 2025 pp. 6056-6056 10.1200/jco.2025.43.16_suppl.6056

6056 Background: Across many solid tumor malignancies, including head and neck squamous cell carcinoma (HNSCC), clinical trial data has supported the inte...

Comparison of navigation bronchoscopy vs shape sensing robotic assisted bronchoscopy in terms of malignancy diagnoses and lung cancer staging in a safety-net healthcare system.

Kalyani Narra, Paras M. Patel, Samuel Newman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23156

e23156 Background: Two bronchoscopic techniques, electromagnetic navigation bronchoscopy (NB) and shape sensing robotic assisted bronchoscopy (ssRAB), hav...

Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA.

John Paul Y.C. Shen, Johannes Reiter, Joshua Babiarz et al. Jun 01, 2025 pp. 3048-3048 10.1200/jco.2025.43.16_suppl.3048

3048 Background: Clinical validation studies support tumor-informed molecular residual disease (MRD) as a prognostic biomarker for disease recurrence acro...

Real-world data on the treatment of patients with ROS1-positive non-small cell lung cancer.

Daniil Stroyakovskiy, Polina Shilo, Anastasia Danilova et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20685

e20685 Background: ROS1 rearrangements, present in 1–2% of non-small cell lung cancer (NSCLC) cases, are targetable by ALK inhibitors due to the structura...

A phase II study of short-course radiotherapy followed by sintilimab, anlotinib combined with CAPOX as neoadjuvant treatment for locally advanced MSS/pMMR rectal cancer (ZZU-1 study).

Ruihua Zhao, Quanbo Zhou, Yugui Lian et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15659

e15659 Background: Survival and organ function preservation are equally important for locally advanced rectal cancer. However, for microsatellite stable (...

Cobolimab and dostarlimab in the first-line treatment of unresectable hepatoma: A multi-center, single arm, phase 2 trial.

Jared David Acoba, Erin Fukaya, Shaun M. Goodyear et al. Jun 01, 2025 pp. 4099-4099 10.1200/jco.2025.43.16_suppl.4099

4099 Background: TIM-3 is highly expressed in cancer and mediates T cell exhaustion/dysfunction that can be an important m...

Tumor-agnostic therapies in a high-volume Brazilian center: Real-world challenges and opportunities.

Maria Fernanda Botelho Teixeira, Camila Bobato Lara Gismondi, Miguel Zugman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23304

e23304 Background: Advances in precision oncology led to the approval of tumor-agnostic therapies (TAT), challenging conventional drug development. Despit...

Liquid biopsy for early detection and monitoring of lung cancer: A systematic review and meta-analysis.

Inban Pugazhendi, Ashita Agrawal, Amara Sofia et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20019

e20019 Background: Lung cancer is among the most severe and lethal malignancies globally. Liquid biopsy, a non-invasive di...

Oncofertility practice patterns in NCCN cancer centers after the overturn of <i>Roe v. Wade</i> .

Nikita V. Baclig, Jordyn Silverstein, Vrushangi Shah et al. Jun 01, 2025 pp. 1536-1536 10.1200/jco.2025.43.16_suppl.1536

1536 Background: The Supreme Court decision of Dobbs v. Jackson to overturn Roe v. Wade gave states author...

Actionable gene alterations in resected non-small cell lung cancer (AGA-R study).

Ilaria Attili, Gloria Pellizzari, Carla Corvaja et al. Jun 01, 2025 pp. 8035-8035 10.1200/jco.2025.43.16_suppl.8035

8035 Background: To date, molecular testing indication in resected non-small cell lung cancer (NSCLC) is limited to epidermal growth factor receptor (...

Statewide Burden and Trends of Liver Cancer Mortality Attributable to High BMI in the US (1991–2021): Insights from the Global Burden of Disease study, 2021.

Jahnavi Chaudhari, Adit Patel, Adit Dharia et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22569

e22569 Background: Liver cancer remains a leading cause of cancer-related deaths in the United States and high BMI is a key risk factor, which contributes...

Comparative effectiveness and safety of neoadjuvant chemotherapy in combination with pembrolizumab for triple negative breast cancer: A real-world analysis from Alberta, Canada.

Malek B. Hannouf, Shiva Bahmanyar, Ammara Naseer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12629

e12629 Background: The KEYNOTE-522 trial demonstrated improved pathologic complete response (pCR) rate and longer-term survival outcomes with the addition...

Monitoring botensilimab- and balstilimab-induced T-cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer.

Gertjan Rasschaert, Ana Mendizabal-Sasieta, Allyson Peddle et al. Jun 01, 2025 pp. 3527-3527 10.1200/jco.2025.43.16_suppl.3527

3527 Background: Mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) responds poorly to immune checkpoint inhibition (ICI). A better und...

Molecular insights into HR+/HER2+ early-stage breast cancer: Neoadjuvant therapy responses by MammaPrint and BluePrint genomic subtypes.

Laila Samiian, Adam Brufsky, Sahra Uygun et al. Jun 01, 2025 pp. 605-605 10.1200/jco.2025.43.16_suppl.605

605 Background: Clinical HER2+ (cHER2+) early breast cancer (EBC) represents 15-20% of invasive EBC and is typically treated with Neoadjuvant HER2-targete...

Advancing gender equity in cancer research across north Africa: A comprehensive analysis of women’s role and men’s supportive efforts—Final findings from the GEORGiNA-1 study.

Khalid El Bairi, Salma Najem, Laure-Anne Marie Nicole Teuwen et al. Jun 01, 2025 pp. 9044-9044 10.1200/jco.2025.43.16_suppl.9044

9044 Background: Despite limited research on gender inequity in North Africa, this male-dominated region provides a unique context for exploring gender dy...

Patient engagement in accelerating care level activation of precision medicine with patient educational materials in Nigeria: A pilot study.

Gloria Chinyere Okwu, Runcie C.W. Chidebe, Sampson Chinonso Ipiankama et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13583

e13583 Background: Globally, precision medicine (PM) is revolutionizing oncology treatment. PM delivers highly accurate diagnoses and targeted therapies,...

Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial.

Jing Liu, Lele Chang, Xinyu Zhang et al. Jun 01, 2025 pp. 5593-5593 10.1200/jco.2025.43.16_suppl.5593

5593 Background: While PARP inhibitors have shown robust efficacy as maintenance therapy in newly diagnosed ovarian cancer, their potential benefit in the...

Predictors of withdrawal for FDA accelerated approvals of anticancer drugs, 1992-2022.

Alejandra Romano, Ariadna Tibau, Edward Robert Scheffer Cliff et al. Jun 01, 2025 pp. 11024-11024 10.1200/jco.2025.43.16_suppl.11024

11024 Background: The US Food and Drug Administration’s (FDA) accelerated approval pathway facilitates timely access to novel therapies based on surrogate...

Genomic analysis of cfDNA samples from Black patients with metastatic castration-resistant prostate cancer to explore gene alterations associated with tumor progression and treatment resistance.

Franklin W. Huang, Hanbing Song, Tomoki Motegi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17060

e17060 Background: Prostate cancer is among the most commonly diagnosed cancers in the United States, accounting for 29% of new cancer diagnoses among men...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page